Pàgina inicial > Resultats de la cerca: Hudecek, M.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
16 p, 3.4 MB CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors / Dragon, Anna Christina (Hannover Medical School) ; Beermann, Luca Marie (Hannover Medical School) ; Umland, Melina (Hannover Medical School) ; Bonifacius, Agnes (Hannover Medical School) ; Malinconico, Chiara (Hannover Medical School) ; Ruhl, Louisa (Hannover Medical School) ; Kehler, Patrik (Glycotope GmbH) ; Gellert, Johanna (Glycotope GmbH) ; Weiß, Lisa (Glycotope GmbH) ; Mayer-Hain, Sarah (Glycotope GmbH) ; Zimmermann, Katharina (Hannover Medical School) ; Riese, Sebastian (Hannover Medical School) ; Thol, F. (Department of Hematology. Hannover Medical School) ; Beutel, Gernot (Hannover Medical School) ; Maecker-Kolhoff, B. (Department of Pediatric Hematology and Oncology. Hannover Medical School) ; Yamamoto, Felicitas (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Blasczyk, Rainer (Hannover Medical School) ; Schambach, Axel (Hannover Medical School) ; Hust, Michael (Department of Medical Biotechnology. Technical University of Braunschweig) ; Hudecek, Michael (Department of Internal Medicine II. University Hospital of Würzburg) ; Eiz-Vesper, Britta (Hannover Medical School) ; Universitat Autònoma de Barcelona
Introduction: Chimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high expression on the tumor but no expression on healthy cells, since "on-target/off-tumor" cytotoxicity is usually intolerable. [...]
2023 - 10.3389/fimmu.2023.1219165
Frontiers in immunology, Vol. 14 (2023) , p. 1219165  
Registre complet - Creative Commons
2.
11 p, 2.6 MB Development of adaptive immune effector therapies in solid tumors / Comoli, P. (Cell Factory and Pediatric Hematology Oncology. Fondazione IRCCS Policlinico San Matteo) ; Chabannon, Christian (Institut Paoli-Calmettes. Aix-Marseille University. INSERM CBT 1409. Centre for Clinical Investigation in Biotherapy) ; Koehl, U. (Institute of Cellular Therapeutics. Hannover Medical School) ; Lanza, F. (Hematology and Stem Cell Transplant. Romagna Transplant Network) ; Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hudecek, M. (University Hospital Würzburg) ; Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ; Secondino, S. (Università degli Studi di Pavia. Dipartimento di Medicina Interna e Terapia Medica) ; Bonini, C. (University Vita-Salute San Raffaele) ; Pedrazzoli, P. (Università degli Studi di Pavia. Dipartimento di Medicina Interna e Terapia Medica) ; Universitat Autònoma de Barcelona
State-of-the-art treatment strategies have drastically ameliorated the outcome of patients affected by cancer. However, resistant and recurrent solid tumors are generally nonresponsive to conventional therapies. [...]
2019 - 10.1093/annonc/mdz285
Annals of oncology, Vol. 30 Núm. 11 (november 2019) , p. 1740-1750  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
1 Hudecek, Michael
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem